Introduction
Immune checkpoint inhibitors (ICIs) have acquired a central role in the treatment of cancer within the last decade. Over 50 different tumor types have approval for the use of T-cell targeted immunomodulators blocking immune checkpoints like cytotoxic T-lymphocyte associated antigen-4 (CTLA-4), programmed death-1 (PD-1), or programmed death ligand 1 (PD-L1). 1 However, because of their unique mechanism of action, ICIs present their own set of adverse events (AEs), called immune-related adverse events. Neurologic immune-related AEs are an emerging area of interest because of the complexity of the nervous system and the potential for long-term morbidity. 2 , 3 Although the overall incidence of neurologic AE (NAE) is reported to be approximately 1%, 4 NAEs constitute 11% of all the fatal events secondary to ICIs. 3 In a systematic review of literature, Cuzzubbo et al 5 reported that the overall incidence of NAEs of any grade was 3.8% with anti–CTLA-4, 6.1% for anti–PD-1/PD-L1, and 12% with the use of dual checkpoint inhibitors (a combination of anti–PD-1 and anti–CTLA-4 therapy).
The utility of checkpoint inhibitors is being increasingly explored in patients with brain tumors and brain metastases. 6 , 7 Furthermore, multiple clinical trials are exploring the combination of ICIs with radiation therapy and oncolytic viruses to achieve better responses. 6 , 7 Newer molecules inhibiting CTLA-4 or PD-1/PDL-1 are being studied in clinical trials treating multiple tumor types. In such a scenario, it becomes essential to understand the spectrum of NAEs and diagnose it at the onset to prevent long-term morbidity. However, ICI-related NAEs are reported only in systematic reviews and analysis of databases reporting adverse events. This study reports the first meta-analysis examining the NAEs reported in the randomized trials comparing ICIs with chemotherapy, targeted therapy, or placebo.
Methods
Data Sources and Study Selection
In accordance with the Preferred Reported Items for Systematic Reviews and Meta-Analyses ( PRISMA ) reporting guideline ( Figure 1 ), 8 2 authors (S.B.A. and P.L.) independently searched the bibliographic databases (Embase, Ovid, MEDLINE, and Scopus) and trial registries (ClinicalTrials.gov) from inception through March 1, 2020. Published trials fulfilling the PICO criteria (Participants, Intervention, Comparison, and Outcome) were included. Participants included adult patients with any cancer. The intervention included treatment with anti–PD-1/PD-L1 and/or anti-CTLA4 drugs. The comparison included drug regimens that used monotherapy or a combination of chemotherapy, targeted therapy, vaccines, or any medication used to treat that cancer. Trials using placebo or supportive care were also included in the comparison arm. Outcomes included NAEs of any grade or type. Only phase II and III randomized control trials (RCTs) comparing single or dual ICI with the standard of care or placebo were selected. Only those studies where full-text articles were available were screened for the final analysis. In the event of multiple publications from the same trial, only those with the largest sample size were included in our analysis. Any trials whose results were not published in a peer-reviewed journal were excluded. All databases were searched for publications containing anti–PD-1/PD-L1 or anti–CTLA-4 checkpoint inhibitors by using the search string: ipilimumab OR tremelimumab OR nivolumab OR pembrolizumab OR MED10680 OR AMP-224 OR pidilizumab OR atezolimab OR MED14736 OR avelumab OR BMS-936559 AND durvalumab OR MEDI4736 . Two independent reviewers (P.F. and A.M.) examined all selected studies, and disagreements were resolved with mutual consensus or third-party review (M.Z.F.).
Data Extraction and Quality Assessment
Four researchers (S.B.A., P.L., R.C.P., and S.U.B.) independently extracted the following data from the studies included in the analysis into Excel version 2020 (Microsoft Corp) using a standardized form: (1) study information, including the name of the first author, year of publication, category of the trial (phase II or III), interventions received, and the number of participants; (2) characteristics of participants, including median or mean age, gender, race and/or ethnicity, region, smoking status, and ECOG (Eastern Cooperative Oncology Group) performance status; and (3) NAEs of any grade and type, including altered mentation, cerebral edema, cerebrovascular accident, cranial nerve VII palsy, decreased appetite, dizziness, dysgeusia, encephalitis, fatigue, Guillain-Barré syndrome (GBS), headache, insomnia, intracranial hemorrhage, myasthenia gravis, myelitis, paraplegia, paresthesia, peripheral neuropathy, seizure, and trigeminal nerve disorder. To assess the quality of RCTs included in the analysis, 2 authors (S.K. and A.J.) used the Cochrane Collaborations tool (eTable 1 in the Supplement ). 9
We used the Common Terminology of Adverse Events (CTCAE) version 4.0 to define NAEs from systemic therapy as most protocols were written before November 2017 (when CTCAE version 5.0 was introduced). NAE includes the manifestation of any neurologic toxicity secondary to ICI use in the central nervous system, including the brain, brainstem, and spinal cord, extending to the peripheral nervous system, which includes the neuromuscular junction and muscle fibers. Severe toxic effects of the nervous systems included myasthenia gravis, GBS, transverse myelitis, encephalitis, and meningitis. According to CTCAE 4.0, the severity is represented by grades from 1 through 5, with unique clinical descriptions for each AE according to the severity.
Statistical Analysis
Statistical heterogeneity was quantified using I 2 statistics with I values of 25%, 50%, and 75% deemed to represent low, moderate, and high heterogeneity, respectively. Otherwise, given the differences in the study populations, cancers being treated, the wide variety of chemotherapy and ICI agents being used in the individual trials, and the differences in the treatment effects, we expected significant heterogeneity between studies. A random-effects model of DerSimonian and Laird was used for all analyses. The estimates were reported as risk ratio (RR) with 95% CIs. To assess the stability of the pooled values, we performed sensitivity analyses. P > .05 was deemed the threshold for statistical significance in 2-sided tests. An assessment of publication bias was conducted based on a funnel plot (eFigure 1 in the Supplement ). Visual inspection of the funnel plots suggested a low study bias. Our primary outcome was the assessment of NAE of all grades that included peripheral neuropathy, dizziness, headache, stroke, myasthenia gravis, GBS, myelitis, and encephalopathy based on previous reviews in the ICI group compared with the control group. 10 , 11 , 12
Results
Eligible Studies and Study Characteristics
A total of 2876 full-text articles retrieved from the initial database search were analyzed according to PRISMA guidelines ( Figure 1 ). After the final analysis, 39 trials 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 met our inclusion criteria, which comprised 13 110 patients in the control arm and 10 595 patients in the ICI arm ( Table 1 ). Analysis involved 16 RCTs evaluating ICI use treating patients with non–small cell lung cancer that included 9074 patients, subclassification of which showed 4964 in the ICI arm and 4110 in the control arm. By cancer type, 5 RCTs evaluating patients with melanoma, 4 RCTs evaluating patients with renal cell carcinoma, 3 RCTs evaluating multiple myeloma, 2 RCTs each evaluating small cell lung cancer and head and neck cancer, and 1 RCT each evaluating patients with colorectal, gastric, bladder, gastroesophageal junction, urothelial cancer, prostate, and mesothelioma were included in the final analysis.
Table 1.
Characteristics of Included Clinical Trials
Abbreviations: CPI, checkpoint inhibitor; CTLA-4, cytotoxic T-lymphocyte antigen-4; GEJ, gastroesophageal junction; gp100, glycoprotein-100; HNSCC, head and neck squamous cell carcinoma; NSCLC, non–small cell lung cancer; PD-1, programmed cell death protein-1; PD-L1, programmed cell death ligand protein-1; RCC, renal cell cancer.
| Source | Phase/study design | Tumor type | No. of patients | Dose of checkpoint inhibitor | Kind of CPI | Previous treatment | Treatment |
| Chih-Hsin Yang et al, 31 2019 (CAURAL Study group) | Phase III (1:1) | Advanced NSCLC | 29 | Durvalumab 10 mg/kg | PD-L1 | Yes (EGFR-TKI) | Durvalumab + osimertinib vs osimertinib |
| Cohen et al, 32 2019 (KEYNOTE-040) | Phase III (1:1) | Recurrent/relapsed HNSCC | 495 | Pembrolizumab 200 mg | PD-1 | Yes (Platinum therapy) | Pembrolizumab vs SOC |
| Eng et al, 33 2019 (IMblaze370) | Phase III (2:1:1) | Metastatic colorectal cancer | 363 | Atezolizumab 840 mg | PD-L1 | Yes (≥2 previous therapies) | Atezolizumab + cobimetinib vs atezolizumab monotherapy vs regorafenib monotherapy |
| Mateos et al, 34 2019 (KEYNOTE-183) | Phase III (1:1) | Multiple myeloma | 249 | Pembrolizumab 200 mg | PD-1 | Yes (≥2 previous therapies) | Pembrolizumab + pomalidomide + dexamethasone vs pomalidomide + dexamethasone |
| Mok et al, 35 2019 (KEYNOTE-042) | Phase III (1:1) | Locally advanced or metastatic NSCLC | 1274 | Pembrolizumab 200 mg | PD-1 | No | Pembrolizumab vs platinum-based chemotherapy |
| Rini et al, 36 2019 (IMmotion151) | Phase III (1:1) | Metastatic RCC | 915 | Atezolizumab 1200 mg | PD-L1 | No | Atezolizumab + bevacizumab vs sunitinib |
| Rini et al, 37 2019 (KEYNOTE-426) | Phase III (1:1) | Locally advanced or metastatic RCC | 861 | Pembrolizumab 200 mg | PD-1 | No | Pembrolizumab + axitinib vs sunitinib |
| Usmani et al, 15 2019 (KEYNOTE-185) | Phase III (1:1) | Multiple myeloma | 310 | Pembrolizumab 200 mg | PD-1 | No | Pembrolizumab + lenalidomide + dexamethasone vs lenalidomide + dexamethasone |
| West et al, 38 2019 (IMpower130) | Phase III (1:1) | Stage IV, nonsquamous, NSCLC | 723 | Atezolizumab 1200 mg | PD-L1 | No | Atezolizumab + nab-paclitaxel + carboplatin vs nab-paclitaxel + carboplatin |
| Bang et al, 39 2019 (JAVELIN Gastric 300) | Phase III (1:1) | Advanced gastric cancer/GEJ | 371 | Avelumab 10 mg/kg | PD-L1 | Yes (2 lines of treatment) | Avelumab vs paclitaxel or irinotecan or best supportive care |
| Barlesi et al, 40 2019 (JAVELIN Lung 200) | Phase III (1:1) | Stage IIIB/IV or recurrent NSCLC | 792 | Avelumab 10 mg/kg | PD-L1 | Yes (Platinum-based doublet) | Avelumab vs docetaxel |
| Eggermont et al, 41 2019 (KEYNOTE-054) | Phase III (1:1) | Stage III melanoma | 1019 | Pembrolizumab 200 mg | PD-1 | No | Pembrolizumab vs placebo |
| Gandhi et al, 42 2019 (KEYNOTE-189) | Phase III (2:1) | Metastatic non-squamous NSCLC | 616 | Pembrolizumab 200 mg | PD-1 | No | Pembrolizumab + pemetrexed + platinum vs first-line chemotherapy (physician’s choice) |
| Horn et al, 43 2019 (IMpower133) | Phase III (1:1) | Extensive stage small-cell lung cancer | 403 | Atezolizumab 1200 mg | PD-L1 | No | Atezolizumab + carboplatin + etoposide vs carboplatin + etoposide + placebo |
| Motzer et al, 14 2018 (CHECKMATE-214) | Phase III (1:1) | Advanced or metastatic RCC | 1390 | Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg | Dual | No | Ipilimumab + nivolumab vs sunitinib |
| Paz-Ares et al, 44 2018 (KEYNOTE-407) | Phase III (1:1) | Metastatic squamous NSCLC | 559 | Pembrolizumab 200 mg (35 cycles) | PD-1 | No | Pembrolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + paclitaxel or nab-paclitaxel |
| Powles et al, 45 2018 (IMvigor211) | Phase III (1:1) | Locally advanced or metastatic urothelial bladder cancer | 931 | Atezolizumab 1200 mg | PD-L1 | Yes (Platinum-based regimen) | Atezolizumab vs physician choice chemo (vinflunine, paclitaxel, or docetaxel) |
| Shitara et al, 46 2018 (KEYNOTE 061) | Phase III (1:1) | Advanced gastric cancer/GEJ | 395 | Pembrolizumab 200 mg | PD-1 | Yes (Platinum and 5-FU) | Pembrolizumab vs paclitaxel |
| Antonia et al, 47 2017 (PACIFIC) | Phase III (2:1) | Stage III NSCLC | 713 | Durvalumab 10 mg/kg | PD-L1 | No | Durvalumab vs placebo |
| Bang et al, 48 2017 | Phase II (1:1) | Advanced gastric cancer/GEJ | 143 | Ipilimumab 10 mg/kg | CTLA-4 | Yes (≥1 line of chemotherapy) | Ipilimumab vs supportive care (continue 5-FU) |
| Bellmunt et al, 49 2017 (KEYNOTE-045) | Phase III (1:1) | Recurrent or metastatic urothelial carcinoma | 542 | Pembrolizumab 200 mg | PD-1 | Yes | Pembrolizumab vs docetaxel/paclitaxel or vinflunine |
| Carbone et al, 50 2017 CHECKMATE 026 | Phase III | Stage IV or recurrent NSCLC | 1325 | Nivolumab 3 mg/kg | PD-1 | No | Nivolumab vs gemcitabine/paclitaxel/pemetrexed |
| Govindan et al, 51 2017 | Phase III (1:1) | Stage IV/ recurrent squamous NSCLC | 749 | Ipilimumab 10 mg/kg | CTLA-4 | No | Ipilimumab + paclitaxel/carboplatin vs placebo + paclitaxel/carboplatin |
| Hamid et al, 52 2017 (KEYNOTE 002) | Phase II (1:1:1) | Advanced melanoma | 540 | Pembrolizumab 2 mg/kg and 10 mg/kg | PD-1 | Yes (Ipilimumab or BRAF/MEK inhibitors or both) | Pembrolizumab 2 mg/kg vs pembrolizumab 10 mg/kg vs carboplatin/paclitaxel/dacarbazine/temozolomide |
| Maio et al, 53 2017 (DETERMINE) | Phase IIb (2:1) | Relapsed mesothelioma | 571 | Tremelimumab 10 mg/kg | CTLA-4 | Yes (1 or 2 lines of therapy) | Tremelimumab vs placebo |
| Rittmeyer et al, 54 2017 (OAK study group) | Phase III (1:1) | Stage IIIB/ IV or recurrent NSCLC | 1225 | Atezolizumab 1200 mg | PD-L1 | Yes (1 or 2 platinum-based regimens) | Atezolizumab vs docetaxel |
| Fehrenbacher et al, 55 2016 (POPLAR) | Phase II (1:1) | Stage IIIB/IV or recurrent NSCLC | 287 | Atezolizumab 1200 mg | PD-L1 | Yes (Platinum-based regimen) | Atezolizumab vs docetaxel |
| Ferris et al, 56 2016 (CHECKMATE-141) | Phase III (2:1) | Recurrent or stage III/IV HNSCC | 506 | Nivolumab 3 mg/kg | PD-1 | Yes (Platinum-based regimen) | Nivolumab vs cetuximab or methotrexate or docetaxel |
| Herbst et al, 57 2016 (KEYNOTE-010) | Phase II/III (1:1:1) | Advanced NSCLC | 1034 | Pembrolizumab 2 mg/kg and 10 mg/kg | PD-1 | Yes (platinum-containing doublet) | Pembrolizumab 2 mg/kg vs pembrolizumab 10 mg/kg vs docetaxel |
| Langer et al, 58 2016 (KEYNOTE-021) | Phase II, (1:1) | Stage IIIB/IV non-squamous NSCLC | 123 (1:1) | Pembrolizumab 200 mg | PD-1 | No | Pembrolizumab with carboplatin + pemetrexed vs carboplatin + pemetrexed |
| Reck et al, 59 2016 (KEYNOTE-024) | Phase III, (1:1) | Advanced NSCLC | 305 (1:1) | Pembrolizumab 200 mg | PD-1 | No | Pembrolizumab vs platinum-based chemotherapy |
| Reck et al, 60 2016 | Phase III, (1:1) | Small cell lung cancer | 1132 (1:1) | Ipilimumab 10 mg/kg | CTLA-4 | No | Ipilimumab + platinum + etoposide vs placebo + platinum + etoposide |
| Borghaei et al, 61 2015 (CHECKMATE-057) | Phase III (1:1) | NSCLC | 582 (1:1) | Nivolumab 3 mg/kg | PD-1 | Yes (Platinum-based doublet therapy) | Nivolumab vs docetaxel |
| Eggermont et al, 62 2015 (EORTC 18071) | Phase III (1:1) | High-risk stage III melanoma | 951 (1:1) | Ipilimumab 10 mg/kg | CTLA-4 | No | Ipilimumab vs placebo |
| Motzer et al, 13 2015 (CHECKMATE-025) | Phase III (1:1) | Advanced RCC | 821 (1:1) | Nivolumab 3 mg/kg | PD-1 | 1-2 lines of antiangiogenic therapy | Nivolumab vs everolimus |
| Kwon et al, 63 2014 (CA184-043) | Phase III (1:1) | Stage IV, castration resistant prostate cancer | 799 (1:1) | Ipilimumab 10 mg/kg | CTLA-4 | Yes (Docetaxel) | Ipilimumab vs placebo |
| Reck et al, 64 2013 | Phase II (1:1:1) | Extensive small cell lung cancer | 130 (1:1:1) | Ipilimumab 10 mg/kg | CTLA-4 | No | Ipilimumab + carboplatin/paclitaxel (concurrent) vs ipilimumab + carboplatin/paclitaxel (phased) vs placebo + carboplatin/paclitaxel |
| Robert et al, 65 2011 | Phase III (1:1) | Stage IV melanoma | 502 (1:1) | Ipilimumab 10 mg/kg | CTLA-4 | No | Ipilimumab + dacarbazine vs placebo + dacarbazine |
| Hodi et al, 16 2010 | Phase III (3:1:1) | Stage IV/unresectable stage III melanoma | 676 (3:1:1) | Ipilimumab 3 mg/kg | CTLA-4 | Yes | Ipilimumab + gp100 vs ipilimumab monotherapy vs gp100 monotherapy |
To explore the differences in NAEs between patients receiving ICIs and other treatments or placebo, we performed a subgroup analysis of the RCTs that only had ICIs in 1 arm and non-ICI drugs or placebo in the other arm (for example, a trial comparing the combination of chemotherapy and ICIs with chemotherapy alone or ICIs alone was excluded from subgroup analysis). One trial each comparing ICI use with nonchemotherapy drugs, namely, everolimus (CHECKMATE-025 13 ), sunitinib (KEYNOTE-426 37 ), lenalidomide (KEYNOTE-185 15 ), sunitinib (IMmotion-151 36 ), and glycoprotein-100 (Hodi et al 16 ) were reporting NAEs. Due to the differences in the mechanism of action of these drugs, we did not analyze them separately as a subgroup. This study also included subgroup analyses of RCTs exploring the efficacy of ICI with chemotherapy (15 trials) and ICI with placebo (5 trials).
Overview and Demographics
NAEs were reported in 1989 patients (15.2%) in the ICI group and in 2110 patients (19.9%) in the comparative arm ( Table 2 ). In the ICI group, 1400 NAEs (70.4%) were reported with the anti–PD-1/PDL-1 agents compared with 504 events (25.3%) with the anti–CTLA-4 group. The trial reported by Motzer et al 14 evaluated a combination of anti–PD-1/PDL-1 and anti–CTLA-4 agents, reporting cumulative neurotoxicity in 314 patients. Demographic information was only reported in the intention-to-treat (ITT) population (23 733 patients). Among the ITT population, 16 135 [68.0%] were men, and 7866 [33.1%] were categorized as White individuals. The majority of patients were diagnosed with non–small cell lung cancer in both the control group (4060 [37.6%]) and the ICI group (5116 [39.5%]). (The demographics of the patients in the ITT population are listed in eTable 2 in the Supplement .)
Table 2.
Summary of Neurological Adverse Events Reported in the Respective Trials
Abbreviations: CVA, cerebrovascular accidents; GBS, Guillain-Barré Syndrome; ICI, immune checkpoint inhibitors; NA, not applicable.
| Adverse event | Overall neurotoxicity | ICI vs chemotherapy | ICI vs placebo | ||||||
| No. of trials | ICI, No. (%) | Comparator arm, No. (%) | No. of trials | ICI, No. (%) | Chemotherapy, No. (%) | No. of Trials | ICI, No. (%) | Placebo, No. (%) | |
| Overall events | 39 | 1989 (15.0) | 2110 (19.9) | 15 | 317 (6.0) | 757 (17.4) | 5 | 389 (17.5) | 223 (12.4) |
| Paresthesia | 10 | 112 (3.0) | 115 (4.4) | 5 | 27 (1.3) | 63 (4.4) | 2 | 26 (3.4) | 12 (2.1) |
| Peripheral neuropathy | 23 | 302 (3.9) | 622 (10.2) | 13 | 72 (1.4) | 447 (10.8) | 2 | 6 (0.8) | 9 (1.5) |
| Headache | 5 | 736 (11.7) | 406 (8.9) | 5 | 68 (3.5) | 32 (2.2) | 3 | 211 (16.97) | 124 (11.7) |
| Dysgeusia | 16 | 299 (4.9) | 704 (14.4) | 8 | 59 (1.9) | 162 (6.5) | 0 | NA | NA |
| Dizziness | 11 | 241 (6.6) | 112 (4.7) | 5 | 51 (2.8) | 29 (2.5) | 2 | 41 (5.30) | 21 (3.6) |
| Insomnia | 7 | 161 (6.2) | 81 (4.4) | 4 | 63 (4.0) | 30 (2.8) | 1 | 31 (7.89) | 0 |
| Altered mental status | 7 | 76 (3.1) | 37 (2.1) | 3 | 2 (0.2) | 1 (0.1) | 2 | 51 (6.60) | 34 (5.8) |
| Rare neurological adverse events (≤1% incidence) | |||||||||
| Encephalopathy | 7 | 14 (0.6) | 2 (0.1) | 2 | 2 (0.3) | 0 | 2 | 1 (0.26) | 1 (0.4) |
| CVA | 5 | 17 (0.9) | 11 (0.9) | 1 | 1 (0.4) | 0 | 2 | 6 (0.69) | 6 (1.0) |
| Seizures | 4 | 14 (0.9) | 4 (0.4) | 1 | 1 (0.4) | 0 | 2 | 6 (0.78) | 3 (0.5) |
| GBS | 5 | 5 (0.3) | 0 | 1 | 1 (0.4) | 0 | 2 | 2 (0.2) | 0 |
| Cranial nerve VII paresis | 1 | 2 (0.5) | 0 | 0 | NA | NA | 0 | NA | NA |
| Intracranial hemorrhage | 1 | 2 (0.5) | 4 (1.0) | 0 | NA | NA | 1 | 2 (0.5) | 4 (1.0) |
| Cerebral edema | 2 | 7 (0.8) | 3 (0.7) | 0 | NA | NA | 1 | 1 (0.3) | 0 |
| Myelitis | 1 | 0 | 1 (0.3) | 0 | NA | NA | 1 | 0 | 1 (0.3) |
| Myasthenia gravis | 1 | 1 (0.7) | 0 | 0 | NA | NA | 0 | NA | NA |
| Trigeminal neuralgia | 2 | 1 (0.2) | 1 (0.2) | 0 | NA | NA | 1 | 0 | 1 (0.3) |
| Paraplegia | 2 | 4 (0.5) | 7 (1.2) | 0 | NA | NA | 2 | 4 (0.5) | 7 (1.2) |
Meta-analysis of the Outcomes
ICI vs Control Group
Overall, we compared the risk of NAEs with treatment using ICIs compared with the control arm (comprising trials using drug regimens including chemotherapy, targeted therapy, vaccines, or combination therapies) or placebo. All-grade NAEs were significantly lower with ICIs compared with the control arm (15.0% vs 19.9%; RR, 0.59; 95% CI, 0.45-0.77; I 2 = 95%, P < .001) among all recruited studies ( Figure 2 ). Twenty-three trials reported peripheral neuropathy, which was significantly lower in patients in the ICI group compared with those in the control group (4.2% vs 10.5%; RR, 0.30; 95% CI, 0.17-0.51; I 2 = 91%; P < .001) (eFigure 2 in the Supplement ). More patients in the ICI group reported headache than the control group (11.6% vs 8.8%; RR, 1.32; 95% CI, 1.10-1.59; I 2 = 51%; P = .008). Fewer patients in the ICI arm reported dysgeusia compared with those in the control group (4.9% vs 14.4%; RR, 0.41; 95% CI, 0.27-0.63; I 2 = 83%; P < .001).
Eleven RCTs reported dizziness with 6.6% of patients in the ICI arm and 4.7% in the control arm (RR, 1.16; 95% CI, 0.75-1.79; I 2 = 64%; P = .50). Seven trials reported altered mental status with 3.9% of patients in the ICI group and 2.1% in the control (RR, 1.30; 95% CI, 0.85-1.97; I 2 = 2%; P = .22). Paresthesia was reported in 10 trials with 3.0% of patients in the ICI group and 4.4% in the control arm (RR, 0.61; 95% CI, 0.31-1.23; I 2 = 79%; P = .17). Seven trials reported insomnia with 6.2% of patients in the ICI group and 4.4% in the control arm (RR, 1.40; 95% CI, 0.66-2.99; I 2 = 79%; P = .38) (eFigure 2 in the Supplement ). Rare events reported in the trials are listed in Table 2 . These data points were not analyzed further because of the rarity of the events.
We analyzed the overall risk of NAE after removing the incidence of peripheral neuropathy from both the ICI and the control arm. The overall risk of NAE was lower in the ICI arm compared with the control arm (12.8% vs 14.0%; RR, 0.74; 95% CI, 0.56-0.97; I 2 = 93%; P = .03] (eFigure 5 in the Supplement )
Subgroup Analysis
ICI vs Chemotherapy
Fifteen trials comparing ICI use with chemotherapy were analyzed separately. NAEs were reported in 317 patients (6.0%) in the ICI arm and 757 patients (17.4%) in the chemotherapy arm. The overall risk of NAE was significantly lower in the ICI group compared with the chemotherapy arm (RR, 0.22; 95% CI, 0.13-0.39; I 2 = 93%; P < .001) ( Figure 3 A). Twelve trials reported a significantly lower risk of peripheral neuropathy in the ICI arm vs chemotherapy arm (1.4% vs 10.8%; RR, 0.09; 95% CI, 0.05-0.17; I 2 = 74%; P < .001) (eFigure 3 in the Supplement ). Ten trials reported a significantly lower risk of dysgeusia in the ICI arm vs chemotherapy arm (1.9% vs 6.5%; RR, 0.42; 95% CI, 0.21-0.85; I 2 = 68%; P = .02). Five trials reported a significantly lower risk of paresthesia in the ICI arm vs chemotherapy arm (1.3% vs 4.4%; RR, 0.29; 95% CI, 0.13-0.67; I 2 = 58%; P = .003) (eFigure 3 in the Supplement ).
Five trials reported headache with 3.5% of patients in the ICI group and 2.2% in the chemotherapy arm (RR, 1.66; 95 CI, 0.61-4.46; I 2 = 75%; P = .32). Four trials reported insomnia with 4.0% of patients in the ICI group and 2.8% in the chemotherapy arm (RR, 1.39; 95% CI, 0.32-5.97; I 2 = 81%; P = .66). Five trials reported dizziness with 2.8% of patients in the ICI group and 2.5% in the chemotherapy arm (RR, 0.98; 95% CI, 0.24-3.91; I 2 = 75%; P = .97) (eFigure 3 in the Supplement ). Rare events with an incidence of less than 1% were not analyzed ( Table 2 ). We analyzed the overall risk of NAEs after removing the incidence of peripheral neuropathy from both the ICI and the chemotherapy arm. The overall risk of NAEs was lower with the ICI arm compared with the chemotherapy arm (4.8% vs 7.9%; RR, 0.47; 95% CI, 0.56-0.97; I 2 = 90%; P < .001) (eFigure 5 in the Supplement ).
ICI vs Placebo
Five trials comparing ICI with placebo were analyzed separately. NAEs were reported in 389 patients (17.5%) in the ICI arm and 223 patients (12.4%) in the placebo arm. The overall risk of NAE was higher in the ICI group compared with the placebo group (RR, 1.57; 95% CI, 1.30-1.89; I 2 = 26%; P = .25) ( Figure 3 B). Three trials reported a significantly higher risk of headache with ICI (RR, 1.63; 95% CI, 1.32-2.02; I 2 = 4%; P = .35) (eFigure 4 in the Supplement ). These results are considered statistically significant due to a low number of studies in the metanalysis, where confidence interval is considered a superior measure of determining significance. 17 Rare events (like myasthenia gravis, and GBS) and events reported by less than 3 trials were not analyzed ( Table 2 ).
Discussion
To the best of our knowledge, this is the first meta-analysis of NAEs reported in RCTs using ICIs. The overall risk of NAEs was significantly lower in the ICI group. However, the heterogeneity in the comparator arm limits the interpretation of this analysis as several RCTs involved either chemotherapy in both arms or had an immunomodulator, tyrosine kinase inhibitor, or placebo in the comparator arm. Also, most of these trials included patients with relapsed refractory neoplasms who have had previous chemotherapy exposure, which could have contributed to the increased incidence of NAEs. The subgroup analysis of ICIs vs chemotherapy included trials in which patients either received ICIs or chemotherapy. This analysis was done to nullify the confounding effect of having chemotherapy in both arms and to clearly understand the association of NAEs with ICI use. Fifteen trials included in this subgroup showed a significantly lower risk of NAEs in the ICI subgroup. Lastly, the subgroup analysis comparing ICIs with placebo was done to assess the association of ICIs with NAEs in trials where patients in the comparator arm did not receive any treatment or received placebo. This meta-analysis showed a significantly higher risk of NAEs with ICIs than those who received a placebo. These results indicated that although ICI use is associated with an increased risk of NAEs, the risk is much lower when compared with chemotherapy.
The neurologic toxicity in the peripheral nervous system associated with ICI use includes mild to moderate peripheral neuropathy or more catastrophic events like GBS, myositis, and myasthenia gravis. 12 , 18 Acute or chronic peripheral neuropathy occurs in up to 3% of all patients treated with ICIs. 4 , 5 , 11 , 19 In our analysis, the overall risk of peripheral neuropathy was significantly lower in the ICI arm than in the control arm. In the subgroup analysis of RCTs comparing ICIs with chemotherapy, peripheral neuropathy and paresthesia were significantly higher in the chemotherapy arm. A recent pharmacovigilance study reported a higher risk of peripheral neuropathy with the use of ICI. However, the authors acknowledged that they had included GBS in the definition of peripheral neuropathy. 20 In RCTs, peripheral neuropathy and paresthesia are defined by symptoms that arise from damage to the peripheral motor or sensory neurons according to CTCAE criteria. Five trials reported 1 patient each with GBS separate from those who developed peripheral neuropathy. Also, most of the trials in the comparison arms included patients who either received taxanes and platinum during the trial or had received them in previous lines of treatment. The incidence of chemotherapy-induced peripheral neuropathy is estimated to be nearly 19% to 85% depending on the study and highest among patients exposed to taxanes (11% to 87%) and platinum (70% to 100%). 21 , 22 , 23 This explains the lower risk of peripheral neuropathy in both the overall analysis and the subgroup analysis of ICIs vs chemotherapy. We also performed the meta-analysis of all trials and those comparing ICIs with chemotherapy after removing the incidence of peripheral neuropathy (eFigure 5 in the Supplement ). The risk of NAEs remains lower with ICIs, which indicates that peripheral neuropathy alone does not skew our results.
Dysgeusia occurs due to alteration in the taste receptor cells and taste bud cells, which is more common with chemotherapy. 24 We noted a significantly lower risk of dysgeusia with ICI in the overall analysis and in the subgroup of ICIs vs chemotherapy. Retrospective studies have reported dysgeusia in up to 1.6% of patients with ICIs. 25 On the other hand, up to 67% of patients receiving chemotherapy develop dysgeusia of any grade, and 38% of patients develop moderate to severe dysgeusia. 26 , 27 Our results demonstrate that although dysgeusia can occur with ICIs, the risk is lower compared with chemotherapy. Headache is one of the common NAEs from the use of ICIs. It is either associated with the endocrine AEs seen with ICIs or as a separate neurological event. 28 The subgroup analysis of ICIs vs placebo showed a significantly increased risk of headache compared with the placebo group, strengthening the association with ICIs as the causative factor. The use of chemotherapy also increases the risk of having a headache. Therefore the results were not statistically significant in the subgroup of ICIs vs chemotherapy despite a higher incidence of headache with the use of ICIs.
RCTs do not capture rarer adverse events reliably. 29 Myasthenic syndrome is a rare NAE of the peripheral nervous system and is often associated with the highest mortality among all NAEs. 3 , 20 Although our analysis reports only 1 patient in the ICI arm to develop myasthenia gravis, studies from various databases and retrospective reviews indicate the frequency as high as 0.1 to 0.47%. 5 , 11 , 12 , 20 GBS-like syndromes occur in 0.1% to 0.2% of all patients treated with ICI. 12 , 20 In our analysis, only 5 patients in the ICI arm developed GBS-like syndrome. The use of ICIs among the general population is quite different from a controlled environment of an RCT; hence rarer AEs are often better elucidated in database studies. 30
Limitations and Strength
The study has a few limitations. First, in analyzing the cumulative risk of NAEs, several trials are included where chemotherapy was used in both arms, which could lead to an overestimation of risk in the ICI arm. The subgroup analyses of ICIs vs chemotherapy and ICIs vs placebo was done to overcome this limitation. Second, the considerable differences among trials in patient characteristics, studied intervention, cointerventions or background therapy, or outcome assessment likely led to considerable heterogeneity in this meta-analysis. However, reassuringly, in most of the analyses the differences between studies were in the magnitude and not the direction of effects. We ensured strict adherence to the inclusion and exclusion criteria. The third limitation of our study comes from the exclusion of data from unpublished studies, which could introduce what could be described as a “file-drawer problem.” It is hard to check the accuracy of unpublished empirical data, especially when it does not undergo the rigors of the peer review process. We have presented funnel plots (eFigure 1 in the Supplement ) to help the reader understand the publication bias of the included studies. Lastly, as mentioned above, RCTs do not capture rare NAEs adequately. Hence, we cannot reliably analyze these events in this meta-analysis.
Conclusions
This meta-analysis found that the overall risk of NAEs was lower with ICIs than in control groups (containing chemotherapy, targeted therapy, placebo, etc). Subgroup analysis showed that overall, NAEs (including peripheral neuropathy, headache, and dysgeusia) were less common with ICIs than chemotherapy. However, compared with placebo, ICIs were associated with a higher risk of NAEs. Further research is needed to understand the full spectrum of NAEs associated with the use of ICIs, especially the rarer NAEs that are not commonly registered in RCTs.
eFigure 1. Funnel Plots for Included Trials by Subgroup
eFigure 2. Overall Analysis of Incidence of Adverse Events Between Checkpoint Inhibitor and Control Arm
eFigure 3. Subgroup Analysis of Adverse Events Between Checkpoint Inhibitors and Chemotherapy
eFigure 4. Subgroup Analysis of Headache Between Checkpoint Inhibitors and Placebo
eFigure 5. Overall Risk of Neurologic Adverse Events Excluding Incidence of Specific Event Between Checkpoint Inhibitors and Control Arm
eTable 1. Quality Assessment of All Trials Using the Cochrane Collaborations Tool
eTable 2. Pooled Characteristics of the Intention-to-Treat Population
Click here for additional data file.
References
1. Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020;11(1):3801. doi: 10.1038/s41467-020-17670-y
2. Spain L, Tippu Z, Larkin JM, Carr A, Turajlic S. How we treat neurological toxicity from immune checkpoint inhibitors. ESMO Open. 2019;4(suppl 4):e000540. doi: 10.1136/esmoopen-2019-000540
3. Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721-1728. doi: 10.1001/jamaoncol.2018.3923
4. Larkin J, Chmielowski B, Lao CD, et al. Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis. Oncologist. 2017;22(6):709-718. doi: 10.1634/theoncologist.2016-0487
5. Cuzzubbo S, Javeri F, Tissier M, et al. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer. 2017;73:1-8. doi: 10.1016/j.ejca.2016.12.001
6. Lauko A, Thapa B, Venur VA, Ahluwalia MS. Management of brain metastases in the new era of checkpoint inhibition. Curr Neurol Neurosci Rep. 2018;18(10):70. doi: 10.1007/s11910-018-0877-8
7. Martikainen M, Essand M. Virus-based immunotherapy of glioblastoma. Cancers (Basel). 2019;11(2):E186. doi: 10.3390/cancers11020186
8. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700. doi: 10.1136/bmj.b2700
9. Higgins JPT, Altman DG, Gøtzsche PC, et al. ; Cochrane Bias Methods Group; Cochrane Statistical Methods Group . The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi: 10.1136/bmj.d5928
10. Dalakas MC. Neurological complications of immune checkpoint inhibitors: what happens when you ‘take the brakes off’ the immune system. Ther Adv Neurol Disord. 2018;11:1756286418799864. doi: 10.1177/1756286418799864
11. Spain L, Walls G, Julve M, et al. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Ann Oncol. 2017;28(2):377-385. doi: 10.1093/annonc/mdw558
12. Touat M, Talmasov D, Ricard D, Psimaras D. Neurological toxicities associated with immune-checkpoint inhibitors. Curr Opin Neurol. 2017;30(6):659-668. doi: 10.1097/WCO.0000000000000503
13. Motzer RJ, Escudier B, McDermott DF, et al. ; CheckMate 025 Investigators . Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803-1813. doi: 10.1056/NEJMoa1510665
14. Motzer RJ, Rini BI, McDermott DF, et al. ; CheckMate 214 investigators . Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019;20(10):1370-1385. doi: 10.1016/S1470-2045(19)30413-9
15. Usmani SZ, Schjesvold F, Oriol A, et al. ; KEYNOTE-185 Investigators . Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial. Lancet Haematol. 2019;6(9):e448-e458. doi: 10.1016/S2352-3026(19)30109-7
16. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723. doi: 10.1056/NEJMoa1003466
17. von Hippel PT. The heterogeneity statistic I2 can be biased in small meta-analyses. BMC Med Res Methodol. 2015;15(1):35. doi: 10.1186/s12874-015-0024-z
18. Pan PC, Haggiagi A. Neurologic immune-related adverse events associated with immune checkpoint inhibition. Curr Oncol Rep. 2019;21(12):108. doi: 10.1007/s11912-019-0859-2
19. Zimmer L, Goldinger SM, Hofmann L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:210-225. doi: 10.1016/j.ejca.2016.02.024
20. Johnson DB, Manouchehri A, Haugh AM, et al. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer. 2019;7(1):134. doi: 10.1186/s40425-019-0617-x
21. Fallon MT. Neuropathic pain in cancer. Br J Anaesth. 2013;111(1):105-111. doi: 10.1093/bja/aet208
22. Seretny M, Currie GL, Sena ES, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014;155(12):2461-2470. doi: 10.1016/j.pain.2014.09.020
23. Verstappen CC, Heimans JJ, Hoekman K, Postma TJ. Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs. 2003;63(15):1549-1563. doi: 10.2165/00003495-200363150-00003
24. Murtaza B, Hichami A, Khan AS, Ghiringhelli F, Khan NA. Alteration in taste perception in cancer: causes and strategies of treatment. Front Physiol. 2017;8:134-134. doi: 10.3389/fphys.2017.00134
25. Xu Y, Wen N, Sonis ST, Villa A. Oral side effects of immune checkpoint inhibitor therapy (ICIT): an analysis of 4683 patients receiving ICIT for malignancies at Massachusetts General Hospital, Brigham & Women’s Hospital, and the Dana-Farber Cancer Institute, 2011 to 2019. Cancer. 2021;127(11):1796-1804. doi: 10.1002/cncr.33436
26. Bernhardson B-M, Tishelman C, Rutqvist LE. Self-reported taste and smell changes during cancer chemotherapy. Support Care Cancer. 2008;16(3):275-283. doi: 10.1007/s00520-007-0319-7
27. Wickham RS, Rehwaldt M, Kefer C, et al. Taste changes experienced by patients receiving chemotherapy. Oncol Nurs Forum. 1999;26(4):697-706.
28. Puzanov I, Diab A, Abdallah K, et al. ; Society for Immunotherapy of Cancer Toxicity Management Working Group . Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5(1):95. doi: 10.1186/s40425-017-0300-z
29. Cai T, Parast L, Ryan L. Meta-analysis for rare events. Stat Med. 2010;29(20):2078-2089. doi: 10.1002/sim.3964
30. Di Maio M, Perrone F, Conte P. Real-world evidence in oncology: opportunities and limitations. Oncologist. 2020;25(5):e746-e752. doi: 10.1634/theoncologist.2019-0647
31. Yang JC, Shepherd FA, Kim DW, et al. Osimertinib plus durvalumab versus osimertinib monotherapy in EGFR T790M-positive NSCLC following previous EGFR TKI therapy: CAURAL brief report. J Thorac Oncol. 2019;14(5):933-939. doi: 10.1016/j.jtho.2019.02.001
32. Cohen EEW, Soulières D, Le Tourneau C, et al. ; KEYNOTE-040 investigators . Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019;393(10167):156-167. doi: 10.1016/S0140-6736(18)31999-8
33. Eng C, Kim TW, Bendell J, et al. ; IMblaze370 Investigators . Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2019;20(6):849-861. doi: 10.1016/S1470-2045(19)30027-0
34. Mateos MV, Blacklock H, Schjesvold F, et al. ; KEYNOTE-183 Investigators . Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Lancet Haematol. 2019;6(9):e459-e469. doi: 10.1016/S2352-3026(19)30110-3
35. Mok TSK, Wu YL, Kudaba I, et al. ; KEYNOTE-042 Investigators . Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7
36. Rini BI, Powles T, Atkins MB, et al. ; IMmotion151 Study Group . Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019;393(10189):2404-2415. doi: 10.1016/S0140-6736(19)30723-8
37. Rini BI, Plimack ER, Stus V, et al. ; KEYNOTE-426 Investigators . Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116-1127. doi: 10.1056/NEJMoa1816714
38. West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):924-937. doi: 10.1016/S1470-2045(19)30167-6
39. Bang YJ, Ruiz EY, Van Cutsem E, et al. Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Ann Oncol. 2018;29(10):2052-2060. doi: 10.1093/annonc/mdy264
40. Barlesi F, Vansteenkiste J, Spigel D, et al. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. Lancet Oncol. 2018;19(11):1468-1479. doi: 10.1016/S1470-2045(18)30673-9
41. Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage iii melanoma. N Engl J Med. 2018;378(19):1789-1801. doi: 10.1056/NEJMoa1802357
42. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. ; KEYNOTE-189 Investigators . Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078-2092. doi: 10.1056/NEJMoa1801005
43. Horn L, Mansfield AS, Szczęsna A, et al. ; IMpower133 Study Group . First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220-2229. doi: 10.1056/NEJMoa1809064
44. Paz-Ares L, Luft A, Vicente D, et al. ; KEYNOTE-407 Investigators . Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040-2051. doi: 10.1056/NEJMoa1810865
45. Powles T, Durán I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018;391(10122):748-757. doi: 10.1016/S0140-6736(17)33297-X
46. Shitara K, Özgüroğlu M, Bang YJ, et al. ; KEYNOTE-061 investigators . Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392(10142):123-133. doi: 10.1016/S0140-6736(18)31257-1
47. Antonia SJ, Villegas A, Daniel D, et al. ; PACIFIC Investigators . Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379(24):2342-2350. doi: 10.1056/NEJMoa1809697
48. Bang YJ, Cho JY, Kim YH, et al. Efficacy of sequential ipilimumab monotherapy versus best supportive care for unresectable locally advanced/metastatic gastric or gastroesophageal junction cancer. Clin Cancer Res. 2017;23(19):5671-5678. doi: 10.1158/1078-0432.CCR-17-0025
49. Bellmunt J, de Wit R, Vaughn DJ, et al. ; KEYNOTE-045 Investigators . Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015-1026. doi: 10.1056/NEJMoa1613683
50. Carbone DP, Reck M, Paz-Ares L, et al. ; CheckMate 026 Investigators . First-line nivolumab in stage iv or recurrent non-small-cell lung cancer. N Engl J Med. 2017;376(25):2415-2426. doi: 10.1056/NEJMoa1613493
51. Govindan R, Szczesna A, Ahn MJ, et al. Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancer. J Clin Oncol. 2017;35(30):3449-3457. doi: 10.1200/JCO.2016.71.7629
52. Hamid O, Puzanov I, Dummer R, et al. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. Eur J Cancer. 2017;86:37-45. doi: 10.1016/j.ejca.2017.07.022
53. Maio M, Scherpereel A, Calabrò L, et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017;18(9):1261-1273. doi: 10.1016/S1470-2045(17)30446-1
54. Rittmeyer A, Barlesi F, Waterkamp D, et al. ; OAK Study Group . Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255-265. doi: 10.1016/S0140-6736(16)32517-X
55. Fehrenbacher L, Spira A, Ballinger M, et al. ; POPLAR Study Group . Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387(10030):1837-1846. doi: 10.1016/S0140-6736(16)00587-0
56. Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856-1867. doi: 10.1056/NEJMoa1602252
57. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1–positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540-1550. doi: 10.1016/S0140-6736(15)01281-7
58. Langer CJ, Gadgeel SM, Borghaei H, et al. ; KEYNOTE-021 investigators . Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17(11):1497-1508. doi: 10.1016/S1470-2045(16)30498-3
59. Reck M, Rodríguez-Abreu D, Robinson AG, et al. ; KEYNOTE-024 Investigators . Pembrolizumab versus chemotherapy for PD-L1–positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823-1833. doi: 10.1056/NEJMoa1606774
60. Reck M, Luft A, Szczesna A, et al. Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol. 2016;34(31):3740-3748. doi: 10.1200/JCO.2016.67.6601
61. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627-1639. doi: 10.1056/NEJMoa1507643
62. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16(5):522-530. doi: 10.1016/S1470-2045(15)70122-1
63. Kwon ED, Drake CG, Scher HI, et al. ; CA184-043 Investigators . Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(7):700-712. doi: 10.1016/S1470-2045(14)70189-5
64. Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol. 2013;24(1):75-83. doi: 10.1093/annonc/mds213
65. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517-2526. doi: 10.1056/NEJMoa1104621
Associated Data
Supplementary Materials
eFigure 1. Funnel Plots for Included Trials by Subgroup
eFigure 2. Overall Analysis of Incidence of Adverse Events Between Checkpoint Inhibitor and Control Arm
eFigure 3. Subgroup Analysis of Adverse Events Between Checkpoint Inhibitors and Chemotherapy
eFigure 4. Subgroup Analysis of Headache Between Checkpoint Inhibitors and Placebo
eFigure 5. Overall Risk of Neurologic Adverse Events Excluding Incidence of Specific Event Between Checkpoint Inhibitors and Control Arm
eTable 1. Quality Assessment of All Trials Using the Cochrane Collaborations Tool
eTable 2. Pooled Characteristics of the Intention-to-Treat Population
Click here for additional data file.